anonymous
Guest
anonymous
Guest
Hem's going down to 2 reps per geography - each will have Tasigna, Promacta and Rydapt. Doesn't appear geographies are changing much
NoIs tenure part of the criteria?
Basically, a 40% downsizing occurred today in the OBU! Not sure who won...those that stayed or those that were displaced?!?!
It wouldn't be hard to sell better oncology therapies elsewhere... dogs here. New launches have been a disaster.
What about the cart-t therapy? I thought that was the talk of oncology?
CAR-T is technical and requires specific skill and knowledge. Idiot reps will not do. Most likely hire a professional team of doc, nurses, PAs, PhDs. The days of cheerleading reps is over in oncology. Face it!
Kisqali, Rydapt and Kymriah all disasters for the business
Have you seen the data for kisqali?? Do you understand it? If you do, you will know there is not much data. It was approved due to unmet needs. Yes a company runs on profits and business. It is not a non profit org. Because of stupid decisions people are losing jobs in this for profit company.A disaster for the sales business or for the patients who are benefitting from the treatment?
R E I M A G I N E !